PDS Biotech Submits Phase 3 Protocol Amendment for Accelerated PDS0101 Approval Pathway

summarizeSummary

PDS Biotechnology submitted a Phase 3 protocol amendment to the FDA, aiming for accelerated approval of its lead cancer immunotherapy, PDS0101, by changing the primary endpoint to progression-free survival.

check_boxKey Events

• Protocol Amendment Submitted

  PDS Biotechnology submitted a protocol amendment for its Phase 3 VERSATILE-003 clinical trial to the U.S. Food and Drug Administration (FDA).

• Pathway to Accelerated Approval

  The proposed amendment changes the progression-free survival (PFS) endpoint to a primary endpoint, potentially providing the basis for accelerated approval of PDS0101.

• FDA Alignment

  This submission follows a constructive Type C meeting with the FDA in December 2025, where the proposed accelerated approval pathway was discussed.

• CEO Optimism on Timeline

  President and CEO Frank Bedu-Addo stated that including PFS as a primary endpoint offers an important opportunity to shorten the duration of the VERSATILE-003 trial.

auto_awesomeAnalysis

PDS Biotechnology has submitted a crucial protocol amendment to the FDA for its lead candidate, PDS0101, in the Phase 3 VERSATILE-003 trial. By changing the primary endpoint to progression-free survival (PFS), the company aims to enable an earlier evaluation with significant statistical power, potentially paving the way for accelerated approval. This strategic move, supported by positive data from a prior trial and constructive dialogue with the FDA, could significantly shorten the development timeline and bring the treatment to market sooner, which is a major positive for a late-stage immunotherapy company.